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Polyﬂuoroalkyl compounds (PFCs) comprise
a class of man-made, fluorinated organic
compounds that have been used in a variety
of consumer and industrial applications.
Although these have been produced for many
years, only recently have reports surfaced sug-
gesting widespread exposure in wildlife and
humans (Butenhoff et al. 2006; Calafat et al.
2007; Giesy and Kannan 2001; Houde et al.
2006; Kannan et al. 2004). Two of the most
widely detected and studied compounds in
this class are perfluorooctane sulfonate
(PFOS) and perfluorooctanoate (PFOA).
PFOS and related compounds (polyfluori-
nated sulfonamides) are surfactants used in
applications ranging from oil and water
repellents for fabrics, apparel, carpets, and
paper coatings to specialty chemical applica-
tions such as insecticides and fire fighting
foams (3M Company 1999). PFOA and its
salts are used as chemical intermediates and
processing aids in the production of ﬂuoro-
polymers and ﬂuoroelastomers.
Both PFOS and PFOA have shown the
potential for developmental toxicity in animal
studies. PFOS has been shown, in rats and
mice, to induce developmental and reproduc-
tive effects, such as reduced birth weight,
decreased gestational length, structural defects,
developmental delays, and increased neonatal
mortality (Fuentes et al. 2006; Grasty et al.
2003; Lau et al. 2003; Luebker et al. 2005a,
2005b; Thibodeaux et al. 2003). Recent stud-
ies have also reported developmental toxicity
from PFOA in rodents, including pregnancy
loss, reduced fetal weight, reduced postnatal
survival, and delays in postnatal growth and
development in offspring (Butenhoff et al.
2004; Lau et al. 2004, 2006). However, such
studies of PFOS and PFOA have been con-
ducted using doses that produce serum con-
centrations much higher than general
population human exposures. There are lim-
ited epidemiologic data on the potential
impacts of PFC exposure on fetal growth and
development. However, one recent occupa-
tional study found no association between
employment in jobs with high exposure to
PFOS before the end of pregnancy and mater-
nally reported birth weight (Grice et al. 2007).
PFOS and PFOA have also been shown
to cause reductions in serum cholesterol
and/or triglycerides in several animal species
(Haughom and Spydevold 1992; Seacat
et al. 2002, 2003; Thibodeaux et al. 2003).
Conversely, a few cross-sectional occupa-
tional studies conducted among ﬂuorochem-
ical production employees have reported
positive relationships between PFOS and/or
PFOA concentrations and serum lipid levels
(Gilliland and Mandel 1996; Olsen et al.
1999, 2003). The fetus is likely to be sensi-
tive to the availability of cholesterol and
triglycerides, which support cellular growth,
differentiation, and adipose accumulation
(Woollett 2001). Disruptions to normal fetal
growth and development have been associ-
ated with effects across the lifespan, includ-
ing adverse neonatal and childhood
outcomes (Hofman et al. 1997; Kramer
et al. 1990) and metabolic diseases in adult-
hood (Barker 2006).
In a previous report, we documented fac-
tors associated with cord serum concentra-
tions of PFOS and PFOA in a population of
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BACKGROUND: Recent studies have reported developmental toxicity among rodents dosed with
perﬂuorooctane sulfonate (PFOS) and perﬂuorooctanoate (PFOA).
OBJECTIVES: We examined the relationship between concentrations of PFOS and PFOA in cord
serum (surrogates for in utero exposures) and gestational age, birth weight, and birth size in
humans.
METHODS: We conducted a hospital-based cross-sectional epidemiologic study of singleton deliveries
in Baltimore, Maryland. Cord serum samples (n = 293) were analyzed for PFOS and PFOA by online
solid-phase extraction, coupled with reversed-phase high-performance liquid chromatography–isotope
dilution tandem mass spectrometry. Maternal characteristics and anthropometric measures were
obtained from medical charts.
RESULTS: After adjusting for potential confounders, both PFOS and PFOA were negatively associ-
ated with birth weight [per ln-unit: β = –69 g, 95% conﬁdence interval (CI), –149 to 10 for PFOS;
β= –104 g, 95% CI, –213 to 5 for PFOA], ponderal index (per ln-unit: β = –0.074 g/cm3 × 100,
95% CI, –0.123 to –0.025 for PFOS; β = –0.070 g/cm3 × 100, 95% CI, –0.138 to –0.001 for
PFOA), and head circumference (per ln-unit: β = –0.32 cm, 95% CI, –0.56 to –0.07 for PFOS; β =
–0.41 cm, 95% CI, –0.76 to –0.07 for PFOA). No associations were observed between either
PFOS or PFOA concentrations and newborn length or gestational age. All associations were inde-
pendent of cord serum lipid concentrations.
CONCLUSIONS: Despite relatively low cord serum concentrations, we observed small negative associ-
ations between both PFOS and PFOA concentrations and birth weight and size. Future studies
should attempt to replicate these ﬁndings in other populations.
KEY WORDS: Birth weight, cord blood, epidemiology, fetal exposure, fetal growth, gestational age, head
circumference, human, length, perﬂuorooctane sulfonate, perﬂuorooctanoate, polyﬂuoroalkyl com-
pounds, ponderal index. Environ Health Perspect 115:1670–1676 (2007). doi:10.1289/ehp.10334
available via http://dx.doi.org/ [Online 31 July 2007]newborn deliveries known as the Baltimore
THREE study (Apelberg et al. 2007). In this
study, we examined the relationship between
these concentrations and gestational age, birth
weight, and measures of birth size, including
head circumference, length, and ponderal
index (a measure of body mass at birth).
Materials and Methods
Subjects. We conducted a cross-sectional
study (the Baltimore THREE Study) of new-
born deliveries at the Johns Hopkins Hospital
in Baltimore, Maryland. This study received
approval from the Johns Hopkins Medicine
Institutional Review Board and received a
waiver from the Health Insurance Portability
and Accountability Act. The study required
the collection only of specimens that other-
wise would have been discarded and informa-
tion from medical records that were available
to hospital personnel. There was no require-
ment for informed consent due to the
anonymization of all samples and data.
Members of a community advisory commit-
tee, who were selected for their specific
knowledge, expertise, and focus on important
child health concerns in Maryland, had the
opportunity to learn about and comment on
this study before it was conducted. Between
26 November 2004 and 16 March 2005, all
singleton, live birth deliveries occurring in the
labor and delivery suite at the hospital were
eligible for participation in the study. We
excluded women who gave birth to multiple
children or women who delivered a single
child but had an initial twin gestation with
fetal loss at ≥ 20 weeks. Newborns with major
congenital anomalies likely to affect fetal
growth were excluded as well.
Over the course of the study period, 609
live births occurred at the Johns Hopkins
Hospital, of which 597 were singleton births.
We obtained cord blood specimens from 341
of these, of which 42 had insufﬁcient volume
for laboratory analyses and were excluded
from this study. Additionally, six births were
excluded due to known major congenital
anomalies (n = 5) or an initial twin gestation
(n = 1), leaving a total of 293 study partici-
pants. We conducted a brief survey of hospital
personnel to understand the major reasons for
missed specimen collection. The most com-
mon explanations included complications dur-
ing delivery, premature birth and/or small size
of the infant resulting in small quantity of
available cord blood, and logistical factors such
as understaffing. The babies who were not
included had somewhat lower gestational ages
and birth weights. In addition, factors associ-
ated with insufﬁcient blood volumes collected
were preterm birth, low birth weight, being
ﬁrst born, and younger age of mother.
Detailed methods for the collection and
analysis of cord blood samples are described
in a prior publication (Apelberg et al. 2007).
Briefly, samples were collected from the
umbilical cord vein by hospital personnel
using a sterile technique immediately after a
singleton birth delivery (Witter et al. 2001).
Within 3 hr, refrigerated specimens were cen-
trifuged and serum was stored at –80°C in
2-mL polypropylene cryovials, previously pre-
screened and shown to be free of PFC conta-
minants. Specimens were transferred on dry
ice to the Centers for Disease Control and
Prevention (CDC) for laboratory analyses.
Medical records. We abstracted maternal
and infant characteristics from clinical data-
bases maintained by the hospital. Maternal
information was abstracted by two study
investigators concurrently (B.J.A., J.B.H.),
and a random 10% sample was verified by
two others (L.R.G., F.R.W.). Additional
information was obtained from forms filled
out by the nursing staff at the time of deliv-
ery. Age, race, education, and parity were
based on self-report. Body mass index (BMI)
was calculated from reported prepregnancy
weight and height. Gestational age was based
on the best obstetric estimate. Infant sex was
abstracted from the mother’s medical record
and confirmed with the infant record.
Information on maternal health conditions
was abstracted from the medical record.
Maternal smoking status at birth was deﬁned
using a combination of the maternal medical
record and cord serum cotinine concentra-
tions. Cotinine concentrations > 10 ng/mL
were categorized as exposure to maternal
active smoking. If the clinical record indicated
that the mother reported smoking at any time
during pregnancy, she was considered an
active smoker regardless of the cotinine con-
centration in cord serum.
Infant anthropometric measures were
abstracted from the infant medical record.
Birth weight in grams obtained from the
maternal record was confirmed with the
infant record. Head circumference and length
in centimeters were abstracted from the infant
record. Ponderal index was calculated as the
ratio of birth weight in grams to length in
centimeters cubed, multiplied by 100 (birth-
weight/length3 × 100). We examined the rela-
tionships among gestational age, birth weight,
length, and head circumference to identify
outlying values, which were veriﬁed using the
infant and maternal record. All congenital
conditions on the birth record were recorded
and reviewed by a clinician blinded to expo-
sure status to determine which subjects had
major malformations and should be excluded
from this study. Because only singleton births
were eligible for this study, we retrospectively
excluded one birth, which, unknown to us at
the time of sample collection, was from a twin
gestation with demise of the other twin at
20 weeks.
Laboratory analysis. Polyﬂuoroalkyl com-
pounds. We analyzed cord serum samples for
PFOS, PFOA, and nine other PFCs using a
modification of the method of Kuklenyik et
al. (2005), described in detail previously
(Apelberg et al. 2007; Kuklenyik et al. 2005).
This analytical methodology has been used to
measure PFCs in large-scale surveys, including
the National Health and Nutrition
Examination Survey (NHANES) (Calafat
et al. 2007). Brieﬂy, without protein precipita-
tion, the analytes in one aliquot of 100 µL of
serum were preconcentrated using automated
solid phase extraction, chromatographically
resolved by reversed-phase high performance
liquid chromatography (HPLC), and detected
by negative-ion TurboIonSpray ionization-iso-
tope dilution-tandem mass spectrometry
(MS/MS). For quantiﬁcation, we used 18O2-
PFOS and 18O2-PFOSA (RTI International,
Research Triangle Park, NC) and 13C2-PFOA
provided by Dupont Co. (Wilmington, DE).
The limit of detection (LOD), calculated as
3S0, where S0 is the standard deviation as the
concentration approaches zero (Taylor 1987),
was 0.2 ng/mL for both PFOS and PFOA
(Kuklenyik et al. 2005); the limit of quantita-
tion was three times the LOD. In these cord
serum samples, the precursor/product ion m/z
transition used for the quantiﬁcation of PFOS
(499/99) had an interference. Therefore,
PFOS concentrations were calculated using
another transition (499/130), normally used
to confirm the presence of PFOS. The stan-
dard accuracies (93–118%) were obtained at
three spike levels [LOD, 1.25 ng/mL
(6.6 ng/mL for PFOS) and 12.5 ng/mL
(50 ng/mL for PFOS)] (Kuklenyik et al.
2005). Quality control (QC) materials [low-
concentration (~ 3 ng/mL to ~ 9 ng/mL)
and high-concentration (~ 10 ng/mL to
~ 30 ng/mL)], prepared from a base calf serum
pool, and reagent blank samples were included
in each analytical batch along with the
unknown samples and evaluated according
to standard statistical probability rules
(Kuklenyik et al. 2005). Under the experi-
mental conditions described above, the coefﬁ-
cients of variation of repeated measurements
of the QC materials, which reﬂect the inter-
batch precision within a period of 9 months,
were 12.9–20.6% (PFOS) and 10.7–11.6%
(PFOA). All laboratory analyses were con-
ducted by investigators blinded to the charac-
teristics of study subjects.
Cotinine. Concentrations of cotinine in
serum were determined using a method
described by Bernert et al. (1997). It employs
HPLC coupled with atmospheric pressure
chemical ionization MS/MS to measure serum
cotinine concentrations with high accuracy
and sensitivity (LOD = 0.015 ng/mL). This
method (Bernert et al. 1997) has been used to
assess exposure to environmental tobacco
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surveys.
Lipids. Serum lipid concentration analyses
were conducted using commercially available
test kits from Roche Diagnostics Corp.
(Indianapolis, IN) for the quantitative determi-
nation of total triglycerides (product no.
011002803-0600) and total cholesterol (prod-
uct no. 011573303-0600). Final determinations
were made on a Hitachi 912 Chemistry
Analyzer (Hitachi, Tokyo, Japan).
Statistical analysis. We used descriptive
statistics appropriate for right-skewed data to
characterize PFOS and PFOA concentrations
and the Kruskall-Wallis test to compare
median concentrations across demographic
characteristics. Spearman rank correlation was
used to estimate the correlation between cord
serum concentrations of the two compounds.
Because PFOS and PFOA concentrations were
skewed to the right, all statistical tests requiring
assumptions of normality were conducted on
natural log-transformed concentrations.
Natural log-transformed concentrations were
also used as independent variables in regression
analysis to minimize the potential inﬂuence of
extreme values on the regression coefﬁcients.
Further, natural log-transformed concentra-
tions provided a better ﬁt than untransformed
data in most regression models, based on the
Akaike Information Criterion (Akaike 1973)
and the model R2. Concentrations below the
LOD for PFOS, PFOA, and cotinine were set
to the LOD divided by the square root of two
for all analyses (Hornung and Reed 1990).
We conducted univariate and multivariate
linear regression analyses to examine associa-
tions between PFOS or PFOA and gestational
age, birth weight, head circumference, length,
and ponderal index. Key determinants of ges-
tational age included in regression models
were smoking status, age, race, prepregnancy
BMI, previous preterm birth, diabetes, and
hypertension. Key determinants of birth
weight and birth size included in the primary
adjusted models were smoking status, age,
gestational age, race, prepregnancy BMI, net
weight gain during pregnancy (weight gain
minus birth weight), height, parity, infant
sex, diabetes, and hypertension. Diabetes was
deﬁned to include subjects with preexisting or
gestational diabetes, assuming that both con-
ditions would result in increased fetal weight
for age. Similarly, hypertension was defined
to include subjects with preeclampsia, preg-
nancy-induced hypertension, and chronic
hypertension, which were expected to result
in decreased weight for age. For consistency,
the same set of covariates was included in the
primary regression model for each end point
other than gestational age, except for delivery
mode [vaginal versus caesarian section (C-sec-
tion)], which was included as a predictor of
head circumference. We also explored the
possibility of an interaction between delivery
mode and cord PFOS or PFOA concentra-
tions on head circumference. Based on the
empirical evidence, a quadratic term for
maternal age was included in regressions of
gestational age, birth weight, head circumfer-
ence, and ponderal index, but not for length.
A quadratic term for gestational age was
included in regressions of head circumference
only. All other terms were included in the
models as linear or categorical (indicator)
variables. We considered maternal education
level as a measure of socioeconomic status,
but it was not included in the final models
because it did not materially change the coef-
ficient estimates. We also conducted regres-
sions before and after controlling for total
lipids, total cholesterol, and triglycerides to
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Table 1. Distribution of study population characteristics by PFOS and PFOA concentrations.
Median (IQR)
Characteristic No. (%) PFOS (ng/mL) PFOA (ng/mL)
Maternal age (years)
< 18 24 (8.2) 5.0 (3.3–7.5) 1.4 (1.1–2.3)
18–35 246 (84.0) 5.0 (3.5–7.9) 1.6 (1.2–2.1)
> 35 23 (7.9) 4.1 (3.3–8.7) 1.6 (0.9–2.0)
Race*
White 60 (20.5) 4.5 (3.1–7.1) 1.5 (1.0–2.2)
Asian 25 (8.5) 6.5 (3.4–12.3) 1.5 (1.1–2.6)
Black 208 (71.0) 5.2 (3.6–7.8) 1.7 (1.3–2.1)
Education
< High school diploma 86 (29.8) 4.6 (3.3–7.1) 1.5 (1.2–1.9)
High school diploma 96 (33.2) 4.9 (3.7–7.9) 1.7 (1.3–2.2)
1–4 years college 65 (22.5) 5.7 (3.5–8.6) 1.6 (1.1–2.2)
≥ 5 years college 42 (14.5) 5.0 (3.4–9.1) 1.6 (1.2–2.4)
BMI** (kg/m2)
Underweight (< 18.5) 16 (5.7) 6.0 (3.6–12.0) 1.8 (1.2–2.4)
Normal (18.5–24.9) 132 (46.6) 4.9 (3.4–7.4) 1.5 (1.1–1.9)
Overweight (25–29.9) 64 (22.6) 5.0 (3.2–8.1) 1.7 (1.2–2.3)
Obese (≥ 30) 71 (25.1) 5.0 (3.8–8.2) 1.8 (1.3–2.2)
Net weight gain (lbs)
< 21.8 142 (49.8) 4.9 (3.4–6.8) 1.6 (1.2–2.1)
≥ 21.8 143 (50.2) 5.4 (3.5–8.9) 1.7 (1.2–2.2)
Maternal height (inches)
< 64 111 (38.4) 5.0 (3.5–8.2) 1.7 (1.2–2.2)
≥ 64 178 (61.6) 4.9 (3.4–7.6) 1.6 (1.2–2.1)
Primiparous**
Yes 122 (41.6) 5.4 (3.4–8.3) 1.7 (1.3–2.4)
No 171 (58.4) 4.6 (3.4–7.4) 1.5 (1.1–2.0)
Smoking status*
Active 55 (18.8) 4.1 (3.3–6.2) 1.4 (1.3–1.9)
Non/passive smoker 238 (81.2) 5.2 (3.5–8.2) 1.6 (1.2–2.2)
Infant sex**
Male 162 (55.3) 4.6 (3.2–7.7) 1.5 (1.1–1.9)
Female 131 (44.7) 5.5 (3.8–8.0) 1.8 (1.4–2.3)
Type of delivery
Vaginal 228 (77.8) 5.0 (3.4–7.8) 1.6 (1.2–2.1)
C-section 65 (22.2) 5.0 (3.4–8.4) 1.7 (1.2–2.5)
Hypertension* (preeclampsia, pregnancy induced, and preexisting)
Yes 33 (11.3) 4.0 (2.7–7.4) 1.3 (0.9–2.3)
No 260 (88.7) 5.2 (3.6–7.9) 1.6 (1.2–2.1)
Diabetes (gestational and preexisting)
Yes 20 (6.8) 3.7 (2.4–8.2) 1.5 (0.7–2.2)
No 273 (93.2) 5.0 (3.5–7.9) 1.6 (1.2–2.1)
Gestational age
Preterm 38 (13.0) 4.3 (3.1–8.0) 1.4 (1.1–1.8)
Full-term 255 (87.0) 5.0 (3.5–7.9) 1.6 (1.2–2.2)
IQR = interquartile range. Missing data were excluded from the calculation of percentages and medians. The following
data were missing: 4 observations for education, 10 for BMI, 8 for net weight gain, and 4 for maternal height. Statistically
signiﬁcant differences (p < 0.05) using the Kruskall-Wallis test denoted by *for PFOS and **for PFOA.
Table 2. Distribution of study end points.
Percentile
End point Mean 10th 25th 50th 75th 90th
Gestational age (days) 272 254 266 275 282 287
Birth weight (g) 3,200 2,488 2,777 3,209 3,562 3,909
Head circumference (cm) 33.5 31.0 32.5 33.5 34.5 35.5
Length (cm) 50.0 47.0 48.5 50.0 52.0 53.5
Ponderal index (g/cm3 × 100) 2.54 2.15 2.37 2.55 2.72 2.89examine the possible role of serum lipids as a
mediator of any relationships between PFOS
or PFOA concentrations and birth weight
and size.
A small number (< 4%) of participants
were missing data on prepregnancy weight,
height, and/or net weight gain during preg-
nancy, which are important predictors of
birth weight and size. We imputed the miss-
ing data with the median value of height,
weight, and/or weight gain. As a sensitivity
analysis, we examined the impact of imputing
BMI or weight gain with extreme values and
found no material effect on the regression
coefﬁcients for PFOS or PFOA.
Regression diagnostics were conducted for
all models, including examination of ﬁt, het-
eroskedasticity, and influence. Statistical
analyses were performed using STATA ver-
sion 8.0 (StataCorp., College Station, TX).
Results
PFOA was detected in 100% of cord blood
serum samples, and PFOS was detected in
> 99% of samples. The median PFOA con-
centration was 1.6 ng/mL (range, 0.3 to
7.1 ng/mL) and the median PFOS concentra-
tion was 5 ng/mL [range, < LOD (0.2) to
34.8 ng/mL]. Concentrations of PFOS and
PFOA in cord serum were highly correlated
(Spearman rank correlation coefﬁcient, 0.58;
p < 0.01).
Table 1 shows the characteristics of the
study population stratified by median (and
interquartile range) cord PFOS and PFOA con-
centrations. Statistically signiﬁcant differences
(p < 0.05) in median PFOS concentrations
were observed by race, smoking status, and
hypertension, and differences in median PFOA
concentrations were observed by BMI category,
parity, and infant sex. The distribution of fetal
growth indices are shown in Table 2.
Table 3 shows univariate and multivariate
regression model results of gestational age,
birth weight, length, head circumference, and
ponderal index on natural log-transformed
PFOS and PFOA concentrations. The coefﬁ-
cients from these regression models are equiva-
lent to a change in the end point associated
with a 2.7-fold increase in PFOS or PFOA.
To present these findings on the arithmetic
scale for PFOS and PFOA, we also converted
the adjusted coefﬁcients into the estimated dif-
ference in each end point associated with an
increase from the 25th to 75th percentile of
concentration (Table 3). This corresponds to
an increase in concentration from 3.4 to
7.9 ng/mL for PFOS and from 1.2 to 2.1
ng/mL for PFOA. Multivariate models of
birth weight and size are presented both
adjusted for gestational age only and fully
adjusted as described above.
A non-statistically signiﬁcant positive asso-
ciation was observed between PFOS and
PFOA and gestational age, which diminished
with adjustment for key predictors of gesta-
tional age. After adjusting for gestational age,
both chemicals were negatively associated with
birth weight (p < 0.05). Further adjustment for
additional covariates resulted in an attenuation
of this association. In the fully adjusted model,
a ln-unit increase in cord concentration was
associated with a decrease in mean birth weight
of 69 g [95% conﬁdence interval (CI), –149 to
10) for PFOS and 104 g (95% CI, –213 to 5)
for PFOA. For head circumference, a negative
association was observed with PFOS in multi-
variate analyses. Under the fully adjusted
model, an increase in one ln-unit of PFOS was
associated with a decrease in mean head cir-
cumference of 0.32 cm (95% CI, –0.56 to
–0.07). For PFOA, a negative association was
observed in both univariate and multivariate
analyses. In the fully adjusted model, a ln-unit
increase in PFOA was associated with a
decrease in mean head circumference of
0.41 cm (95% CI, –0.76 to –0.07). The asso-
ciation between PFOA and head circumfer-
ence was also consistent with a curvilinear
relationship on the log scale, which was con-
firmed by inclusion of a quadratic term (p <
0.05) in the model (data not shown). Negative
associations were observed for both PFOS and
PFOA with ponderal index in univariate and
multivariate models. After full adjustment, a
ln-unit increase in PFOS concentration was
associated with a decrease in average ponderal
index (g/cm3 × 100) of 0.074 (95% CI,
–0.123 to –0.025). An increase in PFOA equal
to one ln-unit was associated with a decrease in
mean ponderal index (g/cm3 × 100) of 0.070
(95% CI, –0.138 to –0.001). In contrast, nei-
ther PFOS nor PFOA was signiﬁcantly associ-
ated with newborn length in univariate or
multivariate models (Table 3). The predicted
values from selected regression models are plot-
ted across the full range of ln(PFOS) and
ln(PFOA) concentrations in Figure 1.
We examined the relationships between
PFOS and PFOA concentrations with serum
total cholesterol, triglycerides, and total lipids
Polyfluoroalkyl compounds and fetal growth
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Table 3. Estimated change in mean gestational age, birth weight, and birth size parameters with a change in PFOS or PFOA concentrations equal to one ln-unit or
from the 25th to 75th percentile.
PFOS PFOA
Change in end point (95% CI) Per increase from the  Change in end point (95% CI) Per increase from the 
Model per ln-unita 25th to 75th percentile (IQR)b per ln-unita 25th to 75th percentile (IQR)b
Gestational age (days)
Univariate 2.0 (–0.4 to 4.4) 1.7 (–0.3 to 3.7) 2.4 (–0.8 to 5.7) 1.4 (–0.4 to 3.2)
Adjustedc 1.1 (–1.2 to 3.4) 0.9 (–1.1 to 2.9) 1.9 (–1.3 to 5.0) 1.0 (–0.7 to 2.8)
Birth weight (g)
Univariate –37 (–139 to 64) –31 (–117 to 54) –97 (–234 to 40) –54 (–131 to 23)
Adjusted for GA –89 (–170 to –8)* –75 (–143 to –7)* –161 (–270 to –52)* –90 (–151 to –29)*
Fully adjustedd –69 (–149 to 10) –58 (–125 to 9) –104 (–213 to 5) –58 (–119 to 3)
Head circumference (cm)
Univariate –0.22 (–0.52 to 0.07) –0.19 (–0.44 to 0.06) –0.46 (–0.87 to –0.06)* –0.26 (–0.48 to –0.03)*
Adjusted for GA –0.34 (–0.59 to –0.08)* –0.28 (–0.50 to –0.07)* –0.54 (–0.89 to –0.19)* –0.30 (–0.50 to –0.10)*
Fully adjustedd –0.32 (–0.56 to –0.07)* –0.27 (–0.48 to –0.06)* –0.41 (–0.76 to –0.07)* –0.23 (–0.42 to –0.04)*
Length (cm)
Univariate 0.25 (–0.21 to 0.72) 0.21 (–0.18 to 0.6) –0.06 (–0.69 to 0.57) –0.03 (–0.39 to 0.32)
Adjusted for GA 0.05 (–0.33 to 0.44) 0.05 (–0.28 to 0.37) –0.30 (–0.82 to 0.22) –0.17 (–0.46 to 0.12)
Fully adjustedd 0.13 (–0.26 to 0.52) 0.11 (–0.22 to 0.44) –0.10 (–0.64 to 0.44) –0.06 (–0.36 to 0.24)
Ponderal index (g/cm3 × 100)
Univariate –0.070 (–0.119 to –0.021)* –0.059 (–0.101 to –0.018)* –0.074 (–0.140 to –0.007)* –0.041 (–0.078 to –0.004)*
Adjusted for GA –0.080 (–0.127 to –0.033)* –0.067 (–0.107 to –0.028)* –0.085 (–0.150 to –0.020)* –0.048 (–0.084 to –0.011)*
Fully adjustedd –0.074 (–0.123 to –0.025)* –0.062 (–0.104 to –0.021)* –0.070 (–0.138 to –0.001)* –0.039 (–0.077 to –0.001)*
Abbreviations: GA, gestational age; IQR, interquartile range; ln-unit = natural log unit.
aRepresents the change in the end point associated with a unit increase in ln(PFOS) or ln(PFOA), which is equivalent to a 2.7-fold increase in PFOS or PFOA. bInterquartile range is
3.4–7.9 ng/mL for PFOS and 1.2–2.1 ng/mL for PFOA. cAdjusted for maternal age, BMI, race, previous preterm birth, smoking, diabetes, and hypertension. dAdjusted for gestational age,
maternal age, BMI, race, parity, smoking, baby sex, height, net weight gain, diabetes, and hypertension. For head circumference, adjusted model also includes delivery mode (C-section/
vaginal). *Statistically signiﬁcant (p < 0.05). and found no evidence of an association
between chemical exposure and any of these
biomarkers. Consequently, adjusting for these
measures had no impact on the associations
observed between PFOS or PFOA and the
end points under study [see Supplemental
Material (online at http://www.ehponline.
org/docs/2007/10334/suppl.pdf)].
As expected, delivery mode was associated
with head circumference, with babies born by
C-section having larger head circumferences,
on average, compared with vaginal deliveries,
after adjusting for potential confounders.
Because of the potential for increased mea-
surement error due to head molding in vagi-
nal deliveries, we included an interaction term
between PFOS and PFOA with delivery
mode, which was statistically signiﬁcant (p <
0.05). Surprisingly, the negative association
was restricted to vaginal births. Among vagi-
nal births, both PFOS and PFOA were nega-
tively associated with head circumference
[–0.46 cm per ln-unit PFOS (95% CI –0.73
to –0.19); –0.62 cm per ln-unit PFOA (95%
CI –1.0 to –0.23)]. Among C-sections, there
was a nonsignificant positive association
between both PFOS and PFOA and head cir-
cumference. To further explore this issue, we
evaluated whether this statistical interaction
was also present for birth weight and ponderal
index (data not shown). For birth weight,
some evidence of an interaction in the same
direction was observed with PFOA (p < 0.05)
and PFOS (p = 0.08). No evidence of an
interaction was observed for ponderal index.
Discussion
In a previous study, we documented the mag-
nitude and determinants of fetal cord serum
concentrations of PFOS and PFOA among
deliveries occurring at a hospital in Baltimore,
Maryland (Apelberg et al. 2007). In this study,
we examined the relationship between these
concentrations and gestational age, birth
weight, and birth size. Our results showed neg-
ative associations between both PFOS and
PFOA concentrations and birth weight and
ponderal index, after adjusting for potential
confounders. We also observed a negative asso-
ciation between both PFOS and PFOA con-
centrations and head circumference. For
reasons unknown, the negative associations
with birth weight and head circumference were
observed only among vaginal deliveries.
However, these comprised most of our popula-
tion (77.8%). This ﬁnding could be attributed
to chance or could be associated with under-
lying complications that led to a delivery by
C-section in our population. By contrast, no
signiﬁcant associations were observed between
either PFOS or PFOA concentrations and
newborn length or gestational age. Adjusting
for gestational age had the greatest impact on
the association between PFOS and PFOA con-
centrations and birth weight and size, which
tended to strengthen the associations observed.
Head circumference has been used as a
measure of brain growth and development
(Lindley et al. 1999). Future studies will be
needed to evaluate whether this ﬁnding can be
conﬁrmed and, if so, whether there are associ-
ated alterations in neurodevelopment.
Ponderal index has been used by clinicians and
epidemiologists as a measure of thinness at
birth and an indicator of disproportionate or
asymmetric growth restriction. Fetal weight
and soft tissue mass increase dramatically in the
third trimester and the body becomes more
proportional. It has been hypothesized that
early insults during gestation result in symmet-
ric growth restriction and later insults result in
asymmetric growth restriction, but some
empirical evidence conflicts with this notion
about the timing of fetal growth disruption
(Cunningham et al. 2001; Vik et al. 1997).
Kramer et al. (1989) showed that dispropor-
tionality increased with increasing severity of
growth restriction, suggesting the presence of a
continuum of fetal growth restriction, rather
than two distinct patterns. Regardless, several
studies have shown associations between low
ponderal index and risk of adverse perinatal
outcomes (Cheung et al. 2002; Fay et al. 1991;
Nieto et al. 1998; Villar et al. 1990).
The toxicology literature provides evidence
of developmental effects among animals dosed
with PFOS and PFOA, albeit at substantially
higher levels than observed here (Butenhoff
et al. 2004; Fuentes et al. 2006; Grasty et al.
2003; Lau et al. 2003, 2004, 2006; Luebker
et al. 2005a, 2005b; Thibodeaux et al. 2003).
For example, Luebker et al. (2005b) estimated
a BMDL5 (lower bound of the benchmark
dose associated with a 5% change in response)
for PFOS and birth weight in rats of
0.39 mg/kg/day, equivalent to a rat fetal serum
concentration of about 34,000 ng/mL.
Butenhoff et al. (2004) reported BMDL10s for
several postnatal developmental end points for
PFOA in rats, ranging from 22 to 44
mg/kg/day, equivalent to rat fetal serum con-
centrations from 29,000 to 59,000 ng/mL.
Thus, the serum concentrations of these com-
pounds associated with developmental effects
in rats are several orders of magnitude higher
than the concentrations observed here.
Apelberg et al.
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Figure 1. Birth weight (A, B), head circumference (C, D), and ponderal index (E, F) versus ln(PFOS) and
ln(PFOA) concentrations, before and after adjustment for potential confounders. The black dotted lines denote
the predicted ﬁt from a simple linear regression model. The blue solid lines denote the predicted ﬁt from the
fully adjusted multivariate regression model. Corresponding regression coefﬁcients are presented in Table 3.
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Only limited epidemiologic data on PFCs
and developmental outcomes exist. In one
recent occupational epidemiologic study of
perfluorooctanesulfonyl fluoride manufac-
turing workers, investigators examined the
relationship between occupational PFOS
exposure and self-reported medical conditions
(Grice et al. 2007). Among female respon-
dents, a pregnancy history was ascertained,
including the number of previous pregnancies
and the weight (by recall) of all live births.
The investigators found no association
between cumulative PFOS exposure, based
on a simple job exposure matrix, and mater-
nally reported birth weight. However, several
key determinants of birth weight were not
adjusted for—most notably, the length of ges-
tation—and the extent of follow-up of work-
ers who left the company is unclear (Grice
et al. 2007).
Hypolipidemic effects have been among
the sensitive changes observed in animals in
response to PFOS and PFOA exposure
(Haughom and Spydevold 1992; Seacat et al.
2002, 2003; Thibodeaux et al. 2003). In
occupational studies, associations between
exposure and cholesterol and triglyceride levels
have been observed as well, although in the
opposite direction (Gilliland and Mandel
1996; Olsen et al. 1999, 2003). It is plausible
that if PFOS and PFOA were modifying lipid
metabolism during pregnancy, this could be
related to our observations of reduced weight
for length. However, the observed associations
between PFOS or PFOA and ponderal index
were independent of cord serum lipid levels at
birth. Future studies should examine the pos-
sible role of maternal or fetal lipid concentra-
tions earlier in gestation on the associations
observed here. Alternatively, alteration of fatty
acid metabolism could have secondary nutri-
tional impacts, such as on absorption of fat
soluble vitamins. Further studies could deter-
mine whether levels of fat-soluble vitamins
mediate or modify the associations between
PFOS and PFOA concentrations and weight.
There are some potential limitations to
this cross-sectional study, described below,
which should lead to cautious interpretation
of the results. We used a precise analytical
method for the detection of subparts per bil-
lion PFC concentrations in human serum
(Kuklenyik et al. 2005). In this study, how-
ever, measurement error for PFOS may be
greater than expected based on the method
performance, because a different ion transi-
tion had to be used for quantification. In
addition, anthropometric measurements such
as head circumference and length are likely to
have a larger degree of measurement error
than birth weight, due both to head molding
and the potential for measurement subjectiv-
ity. However, measurement error of either the
exposure or end point would be expected to
bias bivariate associations to the null if the
error is completely random (Brenner and
Loomis 1994). Further, there is a range of
normal variation for these end points in a
population and small changes in weight and
size at birth would not necessarily have clini-
cal signiﬁcance.
Given the relatively low serum concentra-
tions, future studies should examine possible
noncausal mechanisms that may be responsi-
ble for the associations reported here. PFOS
and PFOA have an afﬁnity for protein-bind-
ing and have been shown to accumulate in
protein-rich compartments in biological sys-
tems (Jones et al. 2003; Luebker et al. 2002;
Vanden Heuvel et al. 1992). Because serum
protein levels may be related to nutritional sta-
tus, further studies should examine the poten-
tial role protein concentrations may play in
the associations observed between fetal expo-
sure to these chemicals and fetal growth.
Additionally, poor maternal plasma volume
expansion has been associated with smaller size
at birth (Salas et al. 1993, 2006). If, hypothet-
ically, reduced maternal plasma volume
expansion led to higher cord blood concentra-
tions of PFOS or PFOA, this could account
for the associations observed here. However,
preeclampsia and pregnancy-induced hyper-
tension are both associated with poor maternal
plasma volume expansion (Salas et al. 2006),
yet cord serum PFOS and PFOA concentra-
tions were not elevated among women with
these conditions (Table 1). Placental weight is
also related to maternal plasma volume (Salas
et al. 1993). When preeclampsia and hyper-
tension, as well as placental weight (data not
shown), were added to the regression models,
the associations between PFOS and PFOA
and growth outcomes did not change.
Although we did not find support for this
alternative explanation, future studies could
examine whether plasma–volume changes
during pregnancy may be responsible for the
observed associations.
The use of medical records as the principal
source for data on potential confounders is
likely to result in some degree of misclassiﬁca-
tion. However, we observed the expected rela-
tionships between key predictors and birth
outcomes [see Supplemental Material
(online at http://www.ehponline.org/docs/
2007/10334/suppl.pdf)], suggesting that the
degree of residual confounding is likely to be
small. Although we adjusted for the major
known determinants of birth size and weight,
it remains possible that other unmeasured fac-
tors, such as diet, may be confounding the rela-
tionships observed in this study. The maternal
diet would be expected to be related to weight
and size of the fetus, and it remains possible
that the consumption of contaminated food or
water, including the use of fast-food contain-
ers, is a pathway of exposure to PFOS and/or
PFOA. To confound the relationships
observed, undernutrition would have to be
associated with greater PFOS or PFOA expo-
sure. In this and in a previous publication, we
reported slightly higher concentrations of both
chemicals in underweight and obese mothers
compared with normal weight mothers,
although not all differences were statistically
signiﬁcant (Apelberg et al. 2007).
Finally, our study population represented
a group of individuals with more risk factors
for adverse birth outcomes than the United
States as a whole. Compared with national
estimates, the subjects in our population were
more likely to be black, teenagers, unmarried,
and cigarette smokers (Hoyert et al. 2006).
This is perhaps not surprising given the loca-
tion of the hospital in an urban and economi-
cally disadvantaged community. Although
not quantified, these subjects may also have
higher rates of other risk factors for poor out-
comes, such as substance abuse and infec-
tions. It is not clear what, if any, impact the
presence of concomitant risk factors would
have on the results reported here, but future
studies should be conducted in other settings
to conﬁrm these ﬁndings.
In summary, we observed a small negative
association between PFOS and PFOA con-
centrations in cord blood and birth weight,
ponderal index, and head circumference.
Although lipid metabolism alterations have
been among the more sensitive effects
observed in animal and human data, the asso-
ciations observed here were independent of
cord serum lipid levels. We suggest cautious
interpretation of this study until the ﬁndings
can be replicated in other populations.
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